Daniel Chelsky PhD

Dan brings to Caprion Proteomics deep industrial experience in applying the ProteoCarta™ (formerly CellCarta®) proteomics platform to drug target and biomarker discovery.

Prior to joining the Company, Dan was President and General Manager of BioSignal Packard Inc. (a division of Perkin Elmer), where he oversaw the development of novel technologies and reagents for drug discovery and genomics research, including the AlphaScreen™ and BRET2™ technologies and product lines. Dan also spent five years at Pharmacopeia where, as Senior Director of Biology, his team identified many lead compounds from Pharmacopeia’s million member combinatorial chemistry libraries that resulted in multiple compounds in the clinic. His previous experience also includes positions at Onyx Pharmaceuticals and the DuPont Merck Pharmaceutical Company in cancer research.

Dan received his B.Sc. from the University of California at Santa Barbara and his Ph.D. in Chemistry from the University of Oregon Institute of Molecular Biology and was an American Cancer Society fellow at the University of California at Berkeley.